Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132942) titled 'A Phase II Clinical Study of HZ-H08905 on Efficacy and Safety in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (NHL)' on Sept. 20.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Zhejiang University School of Medicine
Condition:
Non-Hodgkin Lymphoma
Intervention:
Experimental Group (Part 1):Take 200mg (4 tablets) of HZ-H08905 once daily, administered continuously (each cycle is 28 days) until disease progression, intolerance, death, withdrawal of informed consent, the investigator determines that the subject no longer benefits, or...